Combination Therapy for Membranous Nephropathy
Author Information
Author(s): Vink Coralien H., Wetzels Jack F.M., Logt Anne-Els van de
Primary Institution: Radboud University Medical Centre
Hypothesis
Can a low-dose combination therapy with rituximab, cyclophosphamide, and prednisone improve outcomes in patients with membranous nephropathy?
Conclusion
Low-dose triple therapy induced a rapid immunological and clinical remission in most patients with membranous nephropathy.
Supporting Evidence
- 88% of patients achieved immunological remission within 8 weeks.
- 21 out of 26 patients developed proteinuria remission after initial therapy.
- Patients needing additional therapy were identified by PLA2Rab half-life.
Takeaway
This study shows that a special mix of medicines can help most kids with a kidney problem feel better quickly.
Methodology
Single-arm prospective cohort study with high-risk, anti-PLA2R antibodies-positive patients.
Potential Biases
Potential bias due to the single-arm design and lack of randomization.
Limitations
The study had a small number of patients and lacked a validation cohort.
Participant Demographics
15 males, mean age 57 ± 14 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website